A phase II study of nilotinib, a novel tyrosine kin ase inhibitor administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who have also failed dasatinib therapy.

被引：1
|
作者：
Giles, Francis
le Coutre, Philipp
Bhalla, Kapil
Rosti, Gianantonio
Ossenkopplele, G. J.
Alimena, Giuliana
Weitzman, Aaron
Rafferty, Teresa
Zheng, Ming
Kantarjian, Hagop
机构：
[1] MD Anderson Canc Ctr, Houston, TX USA
[2] Campus Virchow Klin, Berlin, Germany
[3] H Lee Moffitt Canc Ctr, Tampa, FL USA
[4] Univ Bologna Policlin, Azienda Osped, Bologna, Italy
[5] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands
[6] Univ Roma La Sapienza, Azienda Policlin Umberto, Rome, Italy
[7] Novartis Pharmaceut, E Hanover, NJ USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.2170.2170
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2170
引用
收藏
页码：615A / 616A
页数：2
相关论文
共 50 条
  • [31] Nilotinib in chronic myelogenous leukemia patients who failed prior imatinib and dasatinib therapy: Updated results of an open-label phase II study
    Abruzzese, E.
    Alimena, G.
    le Coutre, P.
    Bhalla, K. N.
    Ossenkoppele, G. J.
    Haque, A.
    Gallagher, N.
    Kantarjian, H. M.
    Giles, F. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [32] Expanding nilotinib access in clinical trials (ENACT) study in adult patients with imatinib-resistant or -intolerant Philadelphia chromosome-positive (Ph+) chronic myelogenous leukaemia (CML) in chronic phase (CP), accelerated phase (AP), or blast crisis (BC): updated safety analysis
    Smith, G.
    Rizzieri, D. A.
    Alimena, G.
    Al-Ali, H-K
    Zaritskey, A.
    Shen, Z.
    Jootar, S.
    Hsu, Y.
    Veronese, M. L.
    Nicolini, F. E.
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 : 34 - 35
  • [33] Nilotinib is safe and effective in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib resistance or intolerance
    Le Coutre, Philipp
    Giles, Francis J.
    Apperley, Jane
    Ottmann, Oliver G.
    Gattermann, Norbert
    O'Brien, Stephen G.
    Kuliczkowski, Kazimierz
    Larson, Richard A.
    Kim, Dong-Wook
    Haque, Ariful
    Gallagher, Neil
    Baccarani, Michele
    Kantarjian, Hagop M.
    BLOOD, 2007, 110 (11) : 145A - 145A
  • [34] The treatment cost to achieve a complete cytogenetic response in imatinib resistant chronic phase (CP) chronic myelogenous leukemia (CML) patients:: Nilotinib vs. dasatinib
    Mataveli, Fabio D.
    Feng, Weiwei
    Calabro, Alessandra
    Mendes, Wellington
    Hungria, Vania
    BLOOD, 2007, 110 (11) : 977A - 977A
  • [35] Nilotinib in patients (pts) with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib
    Giles, Francis J.
    Larson, Richard A.
    Kantarjian, Hagop M.
    le Coutre, Philipp
    Baccarani, Michele
    Haque, Ariful
    Gallagher, Neil
    Ottmann, Oliver G.
    BLOOD, 2007, 110 (11) : 310A - 310A
  • [36] Phase II study of dasatinib in children and adolescents with newly diagnosed chronic phase chronic myelogenous leukemia (CP-CML) or Philadelphia-positive (Ph plus ) leukemias resistant or intolerant to imatinib
    Rosenberg, J. A.
    Derreumaux, D.
    Gore, L.
    Kearns, P.
    Baruchel, A.
    Barrett, T.
    Zwaan, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [37] A phase I study of tipifarnib in combination with imatinib mesylate (IM) for patients (Pts) with chronic myeloid leukemia (CML) in chronic phase (CP) who failed IM therapy.
    Cortes, J
    Garcia-Manero, G
    O'Brien, S
    Hernandez, I
    Rackoff, W
    Faderl, S
    Thomas, D
    Ferrajoli, A
    Talpaz, M
    Kantarjian, H
    BLOOD, 2004, 104 (11) : 289A - 289A
  • [38] A phase II study of dasatinib in patients with accelerated phase chronic myeloid leukemia (CML) who are resistant or intolerant to imatinib: First results of the CA180005 'START-A' study.
    Guilhot, F
    Apperley, JF
    Shah, N
    Kim, DW
    Grigg, A
    Cheng, S
    Iyer, M
    Cortes, J
    BLOOD, 2005, 106 (11) : 16A - 16A
  • [39] Dasatinib lack of cross intolerance to imatinib in patients (pts) with chronic myelogenous leukemia chronic phase (CML-CP) intolerant to imatinib: a retrospective analysis of safety
    Khoury, H. J.
    Goldberg, S. L.
    Mauro, M. J.
    Stone, R. M.
    Matloub, Y.
    Chen, T.
    Guilhot, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [40] Efficacy of dasatinib (SPRYCEL®) in patients (pts) with chronic phase chronic myelogenous leukemia (CP-CML) resistant to or intolerant of imatinib:: Updated results of the CA180013 'START C' phase II study.
    Baccarani, Michele
    Kantarjian, H. M.
    Apperley, J. F.
    Lipton, J. H.
    Druker, B.
    Countouriotis, A.
    Ezzeddine, R.
    Hochhaus, A.
    BLOOD, 2006, 108 (11) : 53A - 53A
12345